That this House recognises the benefits of prescribed medical cannabis for people suffering with epilepsy and a variety of other conditions; welcomes the legalisation around the use of prescribed medical cannabis on 1 November 2018; regrets the inconsistent MHRA guidelines that risk product availability for patients; further regrets the restrictions on electronic prescriptions for the issuing of medicinal cannabis products; and calls on the Government to use every means necessary to ensure greater consistency from the MHRA to ensure patients suffering from long-term and chronic conditions are aware of medical cannabis as a treatment and incur as little disruption and inconvenience as possible when obtaining it.
Signatories (12)
Source
UK Parliament EDM data